Abbott (NYSE: ABT) shares dipped before hours today on third-quarter results that fell short of the consensus Wall Street forecast.
Shares of ABT fell 2.7% to $129.10 apiece in pre-market trading today. They continued to dip by more than 3.2% to $128.35 by midday. Shares closed the day back up slightly at $129.46 apiece.
The Abbott Park, Illinois-based medtech giant reported profits of $1.64 billion. That equals 94¢ per share on sales of $11.37 billion for the three months ended Sept. 30, 2025.
Abbott’s bottom line dipped just 0.1% year-over-year on a sales increase of 6.9%.
Adjusted to exclude one-time items, earnings per share came in at $1.30. That equaled expectations on Wall Street. Sales fell just shy of forecasts, though, as experts projected $11.39 billion in revenue.
Driving its nearly 7% sales growth overall, worldwide Medical Device sales increased by 14.8% in the quarter. The company attributed this success to double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart. Abbott — one of the largest medtech companies in the world — singled out Diabetes Care and its 20.5% growth in the quarter as continuous glucose monitor (CGM) sales totaled $2 billion.
(MDO’s Medtech Big 100 Special Report takes a deep look at the world’s 100 largest medical device companies, including Abbott. Visit here for a free download.)
“Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance,” said Robert B. Ford, chair and CEO, Abbott. “Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders.”
Abbott reaffirmed its previous full-year 2025 guidance for sales growth between 7.5% and 8%. That excludes COVID-19 testing-related sales. Including those revenues, guidance would land between 6% and 7% growth.
The company also reaffirmed the midpoint of its full-year adjusted EPS guidance, but narrowed the range to between $5.12 and $5.18.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang reiterated their “Buy” rating. They note that management is comfortable with its 2026 outlook and has set forth attainable targets.
The analysts also see opportunities for outperformance through new product introductions in Electrophysiology and Diabetes. Specifically, they see growth opportunities with the Volt ablation catheter’s introduction as well as the planned launch of a dual glucose-ketone sensor for Diabetes.
“Overall, our bullish thesis on the long-term growth trajectory and [Abbott’s] pipeline programs in devices remains solid,” the analysts wrote.
